Lessons from international experience in controlling pharmaceutical expenditure III: Regulating industry

British Medical Journal

Volumn 313, Issue 7048, 1996, Pages 33-35

  Bloor, Karen ^a   Maynard, Alan ^b   Freemantle, Nick ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b Nuffield Provincial Hospitals Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG COST; DRUG EFFICACY; EXPERIENCE; HEALTH CARE COST; HUMAN; LICENSING; PRIORITY JOURNAL; REIMBURSEMENT;

EID: 0029900057     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.313.7048.33     Document Type: Article

References (28)

1. Hutton J, Borowitz M, Olesky I, Luce BR. The pharmaceutical industry and reform: lessons from Europe. Health Aff (Millwood) 1994;13:98-111.
2. Commonwealth of Australia. Draft guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analyses. Canberra: Department of Health, Housing and Community Services, 1990.
3. Commonwealth Department of Health, Housing and Community Services. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analyses. Canberra: AGPS, 1995.
4. Freemantle N, Henry D, Maynard A, Torrance G. Promoting cost-effective prescribing: Britain lags behind? BMJ 1995;310:955-6.
5. Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Toronto: Ontario Ministry of Health, 1991.
6. Detsky A. Guidelines for economic analysis of pharmaceutical products - a draft document for Ontario and Canada. PharmacoEconomics 1993;3: 354-61.
7. Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Toronto: Ontario Ministry of Health, 1994.
8. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. Ottowa: CCOHTA, 1994.
9. Pelc A, Castan J-P. New developments in pricing and drug reimbursement in France. PharmacoEconomics 1994;6(S1):28-35.
10. FDA vulnerable on cost-effectiveness rules? Scrip 1994 Dec 23/27:22.
11. PhRMA's pharmacoeconomic guidelines. Scrip 1995 Apr 14:23.
12. Department of Health. Guidelines far the economic evaluation of pharmaceuticals. London: Department of Health, 1994. (Press release 94/251.)
13. Ziekenfondsraad. Advice on controlling the costs of pharmaceutical aid: summary. Amstelveen: Ziekenfondsraad, 1994.
14. Gross DJ, Ratner J, Perez J, Glavin SL. International pharmaceutical spending controls: France, Germany, Sweden and the United Kingdom. Health Care Financing Review 1994;15:127-41.
15. Jönsson B. Pricing and reimbursement of pharmaceuticals in Sweden. PharmacoEconomics 1994;6(S1):51-60.
16. Rigter H. Recent public policies in the Netherlands to control pharmaceutical pricing and reimbursement. PharmacoEconomics 1994;6(S1):15-21.
17. All ACE-inhibitors same in Germany. Scrip 1995 Mar 10:2.
18. Schulenburg J-M, Graf VD. The German health care system at the crossroads. Health Economics 1994;3:301-4.
19. Garattini L, Salvioni F, Scopelliti D, Garattini S. A comparative analysis of the pharmaceutical market in four European countries. PharmacoEconomics 1994;6:417-23.
20. World Health Organisation. Drug pricing systems in Europe: an overview. Copenhagen: WHO Regional Office for Europe, 1994.
21. Major product prices cut in France. Scrip 1994 Aug 30:2.
22. Department of Health. Pharmaceutical price regulation scheme. London: DoH, ABPI, 1993.
23. Greenfield PR. Report to the secretary of state for social services of the informal working group on effective prescribing. London: DHSS, 1982.
24. Royal Pharmaceutical Society. Pharmaceutical care: the future for community pharmacy. Report of the joint working party on the role of the community pharmaceutical service. London: Royal Pharmaceutical Society, 1992.
25. Lyons JS, Larson DB. Regulations controlling costs of drugs: a perspective from the US. PharmacoEconomics 1992;2:91-4.
26. US Congress. Omnibus Budget Reconciliation Act. Washington, DC: US Congress, 1990.
27. Reeder CE, Lingle EW, Schulz RM, Mauch RP, Nightengale BS, Pedersen CA, et al. Economic impact of cost-containment strategies in third party programmes in the US (Part 1). PharmacoEconomics 1993;4:92-103.
28. General Accounting Office. Medicaid: changes in best prices for outpatient drugs purchased by HMOs and hospitals. Washington, DC: United States General Accounting Office, 1994. (GAO/HEHS-94-194FS.)